| Size | Price | |
|---|---|---|
| 100mg | ||
| Other Sizes |
| Targets |
Pseudoginsenoside F11 targets the central nervous system, where it exhibits neuroprotective and cognitive-enhancing effects. It antagonizes the behavioral actions of morphine and protects against memory dysfunction. Its mechanism of action may involve modulation of neurotransmitter systems and protection against oxidative stress. Its anti-inflammatory effects suggest it may modulate inflammatory pathways in the brain.
|
|---|---|
| ln Vitro |
Biochemical investigations reveal that ginsenoside F11 (ginsenoside A1) can prevent the binding of diprenorphine (DIP) with an IC50 of 6.1 μM, and lower the binding potency of morphine in Chinese hamster ovary (CHO)-μ cells [1].
In vitro, Pseudoginsenoside F11 has been shown to have neuroprotective and anti-inflammatory effects. It is studied in various cell-based models of neuronal injury and inflammation. Its ability to protect against oxidative stress and modulate inflammatory responses has been demonstrated. |
| ln Vivo |
An in vivo model of acute renal failure caused by cisplatin was used. The pretreatment with ginsenoside Pseudoginsenoside F11 (ginsenoside A1) alleviated histopathological damage and decreased blood urea nitrogen and creatinine levels elevated by cisplatin [1]. Using in vivo microdialysis, we examined the impact of ginsenoside F11 (ginsenoside A1) on the emergence of morphine-induced behavioral sensitization and alterations in glutamate levels in the medial prefrontal cortex (mPFC) of freely moving mice. According to the findings, ginsenoside Pseudoginsenoside F11 (ginsenoside A1) can counteract the loss of glutamate in mPFC and the emergence of morphine-induced behavioral sensitization [3].
In vivo, Pseudoginsenoside F11 has been shown to antagonize memory dysfunction induced by scopolamine, morphine, and methamphetamine in mice. It has neuroprotective, anti-inflammatory, antidepressant-like, and cognitive-enhancing effects. These effects make it a promising candidate for the treatment of neurodegenerative and psychiatric disorders. |
| Enzyme Assay |
In vitro non-cell enzyme assays for Pseudoginsenoside F11 are not standard. Its activity is primarily assessed in cell-based and animal studies.
|
| Cell Assay |
In vitro cell-based assays for Pseudoginsenoside F11 use neuronal cell lines to study its neuroprotective effects against various insults, such as oxidative stress or excitotoxicity. Its anti-inflammatory effects are studied in microglia or other immune cells by measuring cytokine production.
|
| Animal Protocol |
In vivo animal studies for Pseudoginsenoside F11 employ models of memory impairment, such as scopolamine-induced amnesia in mice. The compound is administered, and cognitive function is assessed using behavioral tests such as the Morris water maze or passive avoidance test. Its effects on morphine-induced behavior are also studied.
|
| ADME/Pharmacokinetics |
Pseudoginsenoside F11 has a molecular weight of 801.01 g/mol and a molecular formula of C₄₂H₇₂O₁₄. It is an ocotillol-type ginsenoside. The compound should be stored under appropriate conditions, typically at room temperature in the continental US.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Pseudoginsenoside F11 is not extensively detailed. As a natural product from Panax ginseng, it is generally considered to have a good safety profile. However, comprehensive toxicological studies are required for therapeutic development. It is not intended for human therapeutic use without further development.
|
| References |
|
| Additional Infomation |
Reports have indicated that ginsenoside A1 exists in Panax notoginseng, ginseng, and American ginseng, and relevant data is available for reference.
Pseudoginsenoside F11 (Ginsenoside A1) is an ocotillol-type ginsenoside from Panax ginseng. It has neuroprotective, anti-inflammatory, and cognitive-enhancing effects. It antagonizes memory dysfunction induced by scopolamine and morphine. It is not approved for clinical use and is intended for research purposes only. |
| Molecular Formula |
C42H72O14
|
|---|---|
| Molecular Weight |
801.0127
|
| Exact Mass |
800.492
|
| CAS # |
69884-00-0
|
| PubChem CID |
3841360
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
885.3±65.0 °C at 760 mmHg
|
| Flash Point |
489.2±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.599
|
| LogP |
5.27
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
56
|
| Complexity |
1430
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
JBGYSAVRIDZNKA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C42H72O14/c1-19-28(46)30(48)32(50)35(52-19)55-33-31(49)29(47)23(18-43)54-36(33)53-22-17-41(8)24(39(6)13-11-25(45)37(2,3)34(22)39)16-21(44)27-20(10-14-40(27,41)7)42(9)15-12-26(56-42)38(4,5)51/h19-36,43-51H,10-18H2,1-9H3
|
| Chemical Name |
2-[2-[[3,12-dihydroxy-17-[5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-6-methyloxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~62.42 mM)
H2O : ~0.67 mg/mL (~0.84 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.12 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.12 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.12 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2484 mL | 6.2421 mL | 12.4842 mL | |
| 5 mM | 0.2497 mL | 1.2484 mL | 2.4968 mL | |
| 10 mM | 0.1248 mL | 0.6242 mL | 1.2484 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
